Nifty
:
20875.15
Sensex
:
69462.99
-62.55 (-0.30%)
-190.74 (-0.27%)
Nifty
Sensex
:
:
20875.15
69462.99
-62.55 (-0.30%)
-190.74 (-0.27%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
806.50
06-Dec-2023
  • Open
  • High
  • Low
  • Previous Close
  •  780.00
  •  819.00
  •  778.80
  •  779.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1504305
  •  12028.38
  •  880.00
  •  369.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 22,797.78
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 26,594.76
  • 0.31%
  • 2.44

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.09%
  • 14.84%
  • FII
  • DII
  • Others
  • 24.79%
  • 9.78%
  • 1.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.13
  • 5.66
  • 5.88

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.64
  • 7.52
  • 1.80

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.84
  • -20.31
  • -32.58

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.07
  • 14.60
  • 14.33

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.07
  • 1.93
  • 1.78

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.32
  • 8.15
  • 7.59

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
3,207.38
3,017.93
6.28%
3,401.60
2,777.29
22.48%
3,373.72
3,019.15
11.74%
3,463.86
3,173.41
9.15%
Expenses
2,745.09
2,538.96
8.12%
2,770.39
2,345.69
18.11%
2,768.75
2,555.75
8.33%
2,843.61
2,480.26
14.65%
EBITDA
462.28
478.97
-3.48%
631.21
431.60
46.25%
604.97
463.40
30.55%
620.24
693.15
-10.52%
EBIDTM
14.41%
15.87%
18.56%
15.54%
17.93%
15.35%
17.91%
21.84%
Other Income
1.70
86.35
-98.03%
20.87
183.16
-88.61%
-40.21
107.20
-
76.41
13.89
450.11%
Interest
121.46
82.94
46.44%
112.00
59.99
86.70%
109.26
86.85
25.80%
97.27
66.70
45.83%
Depreciation
141.45
145.77
-2.96%
154.65
146.75
5.38%
146.53
131.52
11.41%
162.28
118.93
36.45%
PBT
-124.35
336.62
-
333.41
408.01
-18.28%
-490.77
269.69
-
471.00
343.04
37.30%
Tax
55.95
164.83
-66.06%
160.28
196.91
-18.60%
-87.63
97.13
-
180.23
103.29
74.49%
PAT
-180.30
171.79
-
173.13
211.11
-17.99%
-403.14
172.57
-
290.76
239.75
21.28%
PATM
-5.62%
5.69%
5.09%
7.60%
-11.95%
5.72%
8.39%
7.55%
EPS
-2.90
9.23
-
5.31
6.82
-22.14%
-15.18
5.51
-
9.66
7.86
22.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
13,446.56
12,990.11
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
Net Sales Growth
12.17%
5.57%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
 
Cost Of Goods Sold
4,783.97
4,453.84
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
Gross Profit
8,662.59
8,536.27
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
GP Margin
64.42%
65.71%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
Total Expenditure
11,127.84
10,711.74
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
Power & Fuel Cost
-
227.52
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
93.50
% Of Sales
-
1.75%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
Employee Cost
-
2,780.96
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
% Of Sales
-
21.41%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
Manufacturing Exp.
-
770.68
784.63
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
% Of Sales
-
5.93%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
General & Admin Exp.
-
1,266.05
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
% Of Sales
-
9.75%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
Selling & Distn. Exp.
-
1,154.10
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
% Of Sales
-
8.88%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
Miscellaneous Exp.
-
58.59
78.68
121.44
47.19
33.29
314.55
88.52
38.82
38.48
524.25
% Of Sales
-
0.45%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
EBITDA
2,318.70
2,278.37
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
EBITDA Margin
17.24%
17.54%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
Other Income
58.77
316.79
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
11.48
Interest
439.99
349.58
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
Depreciation
604.91
611.27
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
216.79
PBT
189.29
1,634.31
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
Tax
308.83
491.05
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
Tax Rate
163.15%
56.54%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
PAT
-119.55
297.24
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
PAT before Minority Interest
-206.47
377.40
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
Minority Interest
-86.92
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
PAT Margin
-0.89%
2.29%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
PAT Growth
-115.03%
-68.44%
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
 
EPS
-4.24
10.53
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43
19.22

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
27.12
Total Reserves
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
Non-Current Liabilities
2,680.97
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
Unsecured Loans
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,045.53
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
Trade Payables
2,391.86
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
Other Current Liabilities
1,690.55
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
Short Term Borrowings
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
353.32
Short Term Provisions
613.12
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
259.95
Total Liabilities
17,565.76
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
Net Block
6,202.39
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
Gross Block
11,296.06
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
Accumulated Depreciation
5,093.68
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
Non Current Assets
7,692.04
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
Capital Work in Progress
1,251.26
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
Non Current Investment
44.65
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
0.00
Long Term Loans & Adv.
190.29
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
33.39
Other Non Current Assets
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
20.33
Current Assets
9,873.72
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,977.79
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
Sundry Debtors
4,098.61
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
Cash & Bank
1,469.70
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
Other Current Assets
1,327.62
297.46
671.05
603.30
1,312.40
1,391.61
1,273.61
986.77
774.38
872.81
Short Term Loans & Adv.
966.86
972.41
700.49
544.48
547.18
580.83
590.22
594.89
742.94
768.44
Net Current Assets
4,828.19
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
Total Assets
17,565.76
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
PBT
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
Adjustment
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
709.78
Changes in Working Capital
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
Cash after chg. in Working capital
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
Net Fixed Assets
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
Net Investments
-1,774.62
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
Others
1,466.80
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
Cash from Financing Activity
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
Net Cash Inflow / Outflow
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
Opening Cash & Equivalents
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
Closing Cash & Equivalent
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
109.99
ROA
2.29%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
ROE
4.07%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
ROCE
9.17%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
Fixed Asset Turnover
2.76
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
1.83
Receivable days
44.33
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
115.37
Inventory Days
33.73
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
53.99
Payable days
191.79
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
83.15
Cash Conversion Cycle
-113.73
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
86.21
Total Debt/Equity
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
1.10
Interest Cover
3.48
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86
4.70

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Glenmark Pharmaceuticals recalling 5,856 bottles of Deferasirox tablets in US market
    23rd Nov 2023, 14:58 PM

    The product is used to treat hemochromatosis, or iron overload in the blood

    Read More
  • Glenmark Pharma - Quarterly Results
    10th Nov 2023, 18:57 PM

    Read More
  • Glenmark Pharmaceuticals gets USFDA’s final approval for Fluphenazine Hydrochloride Tablets
    7th Nov 2023, 09:24 AM

    Glenmark’s current portfolio consists of 189 products authorized for distribution in the U.S. marketplace and 50 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark Pharmaceuticals launches Triple-drug FDC of Teneligliptin with Dapagliflozin and Metformin
    18th Oct 2023, 09:19 AM

    This FDC has been launched under the brand name Zita DM

    Read More
  • Glenmark Pharmaceuticals gets final nod for Apremilast Tablets
    17th Oct 2023, 09:29 AM

    Glenmark’s current portfolio consists of 188 products authorized for distribution in the U.S. marketplace

    Read More
  • Glenmark Pharmaceuticals’ arm signs agreement for OX40 antagonist monoclonal antibody portfolio
    12th Oct 2023, 09:25 AM

    With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases

    Read More
  • Glenmark’s arm inks distribution, license agreements with Cosmo for Winlevi
    27th Sep 2023, 12:06 PM

    Cosmo will be the exclusive supplier of the product

    Read More
  • Glenmark Pharmaceuticals to divest 75% stake in Glenmark Life Sciences
    22nd Sep 2023, 10:00 AM

    Glenmark Pharma will own 7.84% in GLS after the divestment

    Read More
  • Glenmark Pharmaceuticals aims to grow revenues by 10-11% in FY24
    11th Sep 2023, 09:41 AM

    The company is also looking at enhancing EBITDA margins while expanding presence in various therapeutic segments like oncology and dermatology

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.